Paclitaxel-loaded iron platinum stealth immunomicelles are potent MRI imaging agents that prevent prostate cancer growth in a PSMA-dependent manner

International Journal of Nanomedicine

Volumn 7, Issue , 2012, Pages 4341-4352

  Taylor, Robert M ^a,b   Sillerud, Laurel O ^a,c  

^a UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^b New Mexico Cancer Nanoscience and Microsystems Training Center   (United States)

^c UNIVERSITY OF NEW MEXICO   (United States)

Author keywords

Iron platinum; Micelle; MRI; Paclitaxel; Prostate cancer

Indexed keywords

MACROGOL; MONOCLONAL ANTIBODY J591; NANOPARTICLE; PACLITAXEL; PROSTATE SPECIFIC MEMBRANE ANTIGEN; SUPERPARAMAGNETIC IRON PLATINUM NANOPARTICLE; SUPERPARAMAGNETIC IRON PLATINUM NANOPARTICLE NANOPARTICLE MICELLE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; CANCER PREVENTION; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DRUG BINDING; DRUG COATING; DRUG CYTOTOXICITY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG LOADING; DRUG POTENCY; DRUG RELEASE; DRUG SCREENING; DRUG SYNTHESIS; DRUG TARGETING; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; MAGNETIC RELAXIVITY; MAGNETISM; MOUSE; NANOENCAPSULATION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PARTICLE SIZE; PHARMACEUTICS; PROSTATE CANCER; TUMOR XENOGRAFT;

ANIMALS; ANTIBODIES; ANTIGENS, SURFACE; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CONTRAST MEDIA; GLUTAMATE CARBOXYPEPTIDASE II; HUMANS; IMMUNOCONJUGATES; IRON; MAGNETIC RESONANCE IMAGING; MAGNETITE NANOPARTICLES; MALE; MICE; MICE, NUDE; MICELLES; PACLITAXEL; PARTICLE SIZE; PLATINUM; PROSTATIC NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MUS; MUS MUSCULUS;

EID: 84870308247     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S34381     Document Type: Article

References (50)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62(1):10-29.
2. Moul JW, Dawson N. Quality of life associated with treatment of castration-resistant prostate cancer: a review of the literature. Cancer Invest. 2012;30(1):1-12.
3. Beltran H, Beer TM, Carducci MA, etal. New therapies for castration-resistant prostate cancer: efficacy and safety. Eur Urol. 2011;60(2):279-290.
4. Dayyani F, Gallick GE, Logothetis CJ, Corn PG. Novel therapies for metastatic castrate-resistant prostate cancer. J Natl Cancer Inst. 2011; 103(22):1665-1675.
5. Gomella LG, Gelpi F, Kelly WK. New treatment options for castrate-resistant prostate cancer: a urology perspective. Can J Urol. 2011;18(4): 5767-5777.
6. Petrylak DP. Current clinical trials in castrate-resistant prostate cancer. Curr Urol Rep. 2011;12(3):173-179.
7. Abeylath SC, Ganta S, Iyer AK, Amiji M. Combinatorial-designed multifunctional polymeric nanosystems for tumor-targeted therapeutic delivery. Acc Chem Res. 2011;44(10):1009-1017.
8. Ho D, Sun X, Sun S. Monodisperse magnetic nanoparticles for theranostic applications. Acc Chem Res. 2011;44(10):875-882.
9. Kievit FM, Zhang M. Surface engineering of iron oxide nanoparticles for targeted cancer therapy. Acc Chem Res. 2011;44(10):853-862.
10. Koo H, Huh MS, Sun IC, etal. In vivo targeted delivery of nanoparticles for theranosis. Acc Chem Res. 2011;44(10):1018-1028.
11. Namiki Y, Fuchigami T, Tada N, etal. Nanomedicine for cancer: lipid-based nanostructures for drug delivery and monitoring. Acc Chem Res. 2011;44(10):1080-1093.
12. Shi J, Xiao Z, Kamaly N, Farokhzad OC. Self-assembled targeted nanoparticles: evolution of technologies and bench to bedside translation. Acc Chem Res. 2011;44(10):1123-1134.
13. Yoo D, Lee JH, Shin TH, Cheon J. Theranostic magnetic nanoparticles. Acc Chem Res. 2011;44(10):863-874.
14. Puri A, Blumenthal R. Polymeric lipid assemblies as novel theranostic tools. Acc Chem Res. 2011;44(10):1071-1079.
15. Sawant RR, Torchilin VP. Multifunctionality of lipid-core micelles for drug delivery and tumour targeting. Mol Membr Biol. 2010;27(7): 232-246.
16. Arias JL, Clares B, Morales ME, Gallardo V, Ruiz MA. Lipid-based drug delivery systems for cancer treatment. Curr Drug Targets. 2011;12(8):1151-1165.
17. Estella-Hermoso de Mendoza A, Campanero MA, Mollinedo F, Blanco-Prieto MJ. Lipid nanomedicines for anticancer drug therapy. J Biomed Nanotechnol. 2009;5(4):323-343.
18. Florence AT, Jani PU. Novel oral drug formulations. Their potential in modulating adverse effects. Drug Saf. 1994;10(3):233-266.
19. Peng XH, Qian X, Mao H, etal. Targeted magnetic iron oxide nanoparticles for tumor imaging and therapy. Int J Nanomedicine. 2008;3(3):311-321.
20. Akhter S, Ahmad Z, Singh A, etal. Cancer targeted metallic nanoparticle: targeting overview, recent advancement and toxicity concern. Curr Pharm Des. 2011;17(18):1834-1850.
21. Hirsjarvi S, Passirani C, Benoit JP. Passive and active tumour targeting with nanocarriers. Curr Drug Discov Technol. 2011;8(3):188-196.
22. Zhang C, Liu T, Gao J, Su Y, Shi C. Recent development and application of magnetic nanoparticles for cell labeling and imaging. Mini Rev Med Chem. 2010;10(3):193-202.
23. Lin MM, Kim do K, El Haj AJ, Dobson J. Development of superparamagnetic iron oxide nanoparticles (SPIONS) for translation to clinical applications. IEEE Trans Nanobioscience. 2008;7(4): 298-305.
24. Shubayev VI, Pisanic TR 2nd, Jin S. Magnetic nanoparticles for theragnostics. Adv Drug Deliv Rev. 2009;61(6):467-477.
25. Mailander V, Landfester K. Interaction of nanoparticles with cells. Biomacromolecules. 2009;10(9):2379-2400.
26. Gandhi SN, Brown MA, Wong JG, Aguirre DA, Sirlin CB. MR contrast agents for liver imaging: what, when, how. Radiographics. 2006;26(6):1621-1636.
27. Tsukada H. Application of pre-clinical PET imaging for drug development. Nihon Shinkei Seishin Yakurigaku Zasshi. 2011;31(5-6): 231-237. Japanese.
28. Taylor RM, Huber DL, Monson TC, Esch V, Sillerud LO. Structural and magnetic characterization of superparamagnetic iron platinum nanoparticle contrast agents for magnetic resonance imaging. J Vac Sci Technol B. 2012;30(2).
29. Taylor RM, Huber DL, Monson TC, Ali AM, Bisoffi M, Sillerud LO. Multifunctional iron platinum stealth immunomicelles: targeted detection of human prostate cancer cells using both fluorescence and magnetic resonance imaging. J Nanopart Res. 2011;13(10):4717-4729.
30. Rasband WS. ImageJ. US National Institutes of Health, Bethesda, Maryland, USA, 1997-2009. Available from: http//rsb.info.nih.gov/ij/. Accessed July 4, 2012.
31. Gossuin Y, Gillis P, Hocq A, Vuong QL, Roch A. Magnetic resonance relaxation properties of superparamagnetic particles. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2009;1(3):299-310.
32. Huang J, Zhong X, Wang L, Yang L, Mao H. Improving the magnetic resonance imaging contrast and detection methods with engineered magnetic nanoparticles. Theranostics. 2012;2(1):86-102.
33. Lee JH, Huh YM, Jun YW, etal. Artificially engineered magnetic nanoparticles for ultra-sensitive molecular imaging. Nat Med. 2007; 13(1):95-99.
34. Carroll MR, Huffstetler PP, Miles WC, etal. The effect of polymer coatings on proton transverse relaxivities of aqueous suspensions of magnetic nanoparticles. Nanotechnology. 2011;22(32):325702.
35. Diezi TA, Bae Y, Kwon GS. Enhanced stability of PEG-block-poly(N-hexyl stearate l-aspartamide) micelles in the presence of serum proteins. Mol Pharm. 2010;7(4):1355-1360.
36. Kastantin M, Missirlis D, Black M, Ananthanarayanan B, Peters D, Tirrell M. Thermodynamic and kinetic stability of DSPE-PEG(2000) micelles in the presence of bovine serum albumin. J Phys Chem B. 2010;114(39):12632-12640.
37. Lu J, Owen SC, Shoichet MS. Stability of self-assembled polymeric micelles in serum. Macromolecules. 2011;44(15):6002-6008.
38. Taylor RM, Severns V, Brown DC, Bisoffi M, Sillerud LO. Prostate cancer targeting motifs: Expression of alpha(nu) beta(3), neurotensin receptor 1, prostate specific membrane antigen, and prostate stem cell antigen in human prostate cancer cell lines and xenografts. Prostate. 2012;72(5):523-532.
39. Couraud S, Planus C, Rioufol C, Mornex F. Platinum salts hypersensitivity. Rev Pneumol Clin. 2008;64(1):20-26. French.
40. Cristaudo A, Sera F, Severino V, De Rocco M, Di Lella E, Picardo M. Occupational hypersensitivity to metal salts, including platinum, in the secondary industry. Allergy. 2005;60(2):159-164.
41. Touraine F, Sainte Laudy J, Boumediene A, etal. Investigation of allergic reactions to platinum salts. Rev Mal Respir. 2006;23(5 Pt 1): 458-462. French.
42. Zhao J, Kim JE, Reed E, Li QQ. Molecular mechanism of antitumor activity of taxanes in lung cancer. Int J Oncol. 2005;27(1): 247-256.
43. Nie S. Understanding and overcoming major barriers in cancer nanomedicine. Nanomedicine (Lond). 2010;5(4):523-528.
44. Akhtar NH, Pail O, Saran A, Tyrell L, Tagawa ST. Prostate-specific membrane antigen-based therapeutics. Adv Urol. 2012;2012:973820.
45. Bander NH, Trabulsi EJ, Kostakoglu L, etal. Targeting metastatic prostate cancer with radiolabeled monoclonal antibody J591 to the extracellular domain of prostate specific membrane antigen. J Urol. 2003;170(5):1717-1721.
46. Bayes M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2007;29(6):427-437.
47. Nanus DM, Milowsky MI, Kostakoglu L, etal. Clinical use of monoclonal antibody HuJ591 therapy: targeting prostate specific membrane antigen. J Urol. 2003;170(6 Pt 2):S84-S88.
48. Rice SL, Roney CA, Daumar P, Lewis JS. The next generation of positron emission tomography radiopharmaceuticals in oncology. Semin Nucl Med. 2011;41(4):265-282.
49. Tagawa ST, Beltran H, Vallabhajosula S, etal. Anti-prostate-specific membrane antigen-based radioimmunotherapy for prostate cancer. Cancer. 2010;116(4 Suppl):1075-1083.
50. Chang SS, O'Keefe DS, Bacich DJ, Reuter VE, Heston WD, Gaudin PB. Prostate-specific membrane antigen is produced in tumor-associated neovasculature. Clin Cancer Res. 1999;5(10):2674-2681.